Accepted Manuscript

Pan-HER-targeted approach for cancer therapy: mechanisms, recent advances and clinical prospect

Wang Manni, Yuzhu Hu, Yu Ting, Ma Xuelei, Wei Xiawei, Wei Yuquan

PII: S0304-3835(18)30472-5

DOI: 10.1016/j.canlet.2018.07.014

Reference: CAN 13988

To appear in: Cancer Letters

Received Date: 6 March 2018

Revised Date: 8 July 2018

Accepted Date: 9 July 2018

Please cite this article as: W. Manni, Y. Hu, Y. Ting, M. Xuelei, W. Xiawei, W. Yuquan, Pan-HERtargeted approach for cancer therapy: mechanisms, recent advances and clinical prospect, *Cancer Letters* (2018), doi: 10.1016/j.canlet.2018.07.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Abstract

The Human Epidermal Growth Factor Receptor family is composed of 4 structurally related receptor tyrosine kinases that are involved in many human cancers. The efficacy and safety of HER inhibitors have been compared in a wide range of clinical trials, suggesting the superior inhibitory ability of multiple- HER-targeting blockade compared with single receptor antagonists. However, many patients are currently resistant to current therapeutic treatment and novel strategies are warranted to conquer the resistance. Thus, we performed a critical review to summarize the molecular involvement of HER family receptors in tumour progression, recent anti-HER drug development based on clinical trials, and the potential resistance mechanisms of anti-HER therapy.

Download English Version:

https://daneshyari.com/en/article/11025936

Download Persian Version:

https://daneshyari.com/article/11025936

Daneshyari.com